Uncategorized

  • Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance

    SOUTH SAN FRANCISCO, March 5, 2018 — Lyric Pharmaceuticals, Inc. (Lyric), a biopharmaceutical company, today announced the completion of...

    by
  • Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU

    Lyric Chief Medical Officer Also Presenting on Role of Ghrelin Agonists in Critical Care SOUTH SAN FRANCISCO, CA, January 23,...

    by
  • Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance (EFI)

    Lyric Chief Medical Officer to Present EFI Incidence Data and Role of Ghrelin Agonists in Critical Care at ASPEN...

    by
  • Lyric Pharmaceuticals Announces $20.4M Series A Funding Round

    SOUTH SAN FRANCISCO, CA, February 26, 2015 – Lyric Pharmaceuticals Inc. today announced the initial closing of a Series...

    by